The C-reactive protein-albumin-lymphocyte (CALLY) index is a clinically feasible biomarker for cancer prognosis.
CALLY index and post-primary percutaneous coronary intervention (pPCI) in-hospital mortality in patients with ST-elevation myocardial infarction (STEMI) remains unclear, despite evidence showing the predictive value of the CALLY index in various cancers.
